Download presentation
Presentation is loading. Please wait.
Published byHelene Mortensen Modified over 5 years ago
1
The Rationale for Adjuvant Chemotherapy in Stage I Non-small Cell Lung Cancer
Leora Horn, MD, MSc, FRCPC, Alan B. Sandler, MD, Joe B. Putnam, MD, FACS, David H. Johnson, MD, FACP Journal of Thoracic Oncology Volume 2, Issue 5, Pages (May 2007) DOI: /01.JTO bb Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions
2
FIGURE 1 Reconstructed survival curves in stage I non-small cell lung cancer by tumor size. Journal of Thoracic Oncology 2007 2, DOI: ( /01.JTO bb) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions
3
FIGURE 2 Survival curves for stage IB (T2N0M0) and IIA (T1N1M0) non-small cell lung cancer. Data obtained from surgical series in the United States (MDA, M.D. Anderson Cancer Center [24 patients] and The Netherlands (D, Dutch group [27 patients]). Journal of Thoracic Oncology 2007 2, DOI: ( /01.JTO bb) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions
4
FIGURE 3 Algorithm for selecting stage I non-small cell lung cancer (NSCLC) patients for postoperative adjuvant chemotherapy. ECOG PS, Eastern Cooperative Oncology Group performance status; CCI, Charlson Comorbidity Index; CT, chemotherapy; VPI, visceral pleural invasion; LVI, lymphovascular invasion; LND, lymph node dissection; LNS, lymph node sampling. Journal of Thoracic Oncology 2007 2, DOI: ( /01.JTO bb) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.